ALT
Biotechnology · Healthcare
Analyst
Truist Securities
Equibles does not estimate personal net worth.
Alex is recorded as Analyst at Truist Securities. Alex has spoken on 7 earnings calls across 7 companies, most recently for Altimmune, Inc. on November 12, 2026. Those appearances were for Altimmune, Inc. (ALT), Scholar Rock Holding Corp (SRRK), Cytokinetics Inc (CYTK), Wave Life Sciences, Inc. (WVE), Harmony Biosciences Holdings, Inc. (HRMY) and 2 other companies. The companies whose calls Alex spoke on are classified in the Healthcare sector.
“Can you provide an update on how you're thinking about potential partnering or the lack thereof in order to optimize the development of PENVI across all three indications?”
“For the 60 to 90 days from script to infusion, do you expect that that will continue up until you get the J code in April, or could that be trimmed down as more payers-established policies?”
“We wanted to know, ahead of the launches and the additional ex-U.S. markets next year, can you provide any color on the discussions that you've had with prescribers, and how would you classify the physician appetite for Mycorso versus how much additional physician education may be needed to drive growth in the market?”
“One follow-up on Jay's question on OnStride 1 and 2. Have those begun enrolling patients? Just we haven't seen any indication in clintrials.gov. And then on the OPEX expenditure, you mentioned the impact of some of the settlements and litigation.”
Truist Securities
Analyst
Transcript header (unverified)
ALT
Biotechnology · Healthcare
CYTK
Biotechnology · Healthcare
INSM
Biotechnology · Healthcare